IP Group plc is a British-based early-stage venture capital firm that commercializes intellectual property originating from universities and research institutions. It invests in deep technology, life sciences, and clean technology companies across the UK, Europe, North America, and Asia-Pacific.
Deal activity increased 50% year-over-year (3 deals in the last 12 months). Average disclosed round size is $45.1M (across 32 rounds with reported amounts).
Portfolio
45
Fund Size
—
Top Stage
Unknown
Last 12 Mo
3
Team
Dr Mark Reilly
Managing Partner
Joyce Xie
Managing Director, Global Capital
Mike Molinari
Managing Director, Australia
Craig Richardson
Partner
Dr Sam Williams
Venture Partner
Lois Day
Venture Partner
Simon Uzcilas
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
54 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Oxa | Series D | — | Mar 2026 |
 Mission Therapeutics | Unknown | $13.3M | Oct 2025 |
 OxCCU | Series B | $28M | Sep 2025 |
 AccelerComm | Unknown | — | Jun 2025 |
 Lumai | Unknown | — | Apr 2025 |
 Navenio | Series A | — | Sep 2023 |
 NextRoll | Growth | $50M | May 2023 |
| OOnspring | Unknown | — | May 2023 |
 Nativo | Growth | $25M | Apr 2023 |
| DDeep Render | Series A | $9M | Mar 2023 |
| IIntrinsic Semiconductor Technologies | Seed | — | Mar 2023 |
 Quantum Motion | Growth | $51M | Feb 2023 |
| Quantum Motion | Series C | $50.5M | Feb 2023 |
 Storm Therapeutics | Series B | $30M | Dec 2022 |
 Pulmocide | Series C | $92M | Dec 2022 |
 SLAMcore | Series A | $16M | May 2022 |
 AMSL Aero | Series B | $23M | Jan 2022 |
 ISSUU | Growth | $31M | Sep 2021 |
 Tile | Unknown | $40M | Sep 2021 |
| AArtios Pharma Limited | Series C | $153M | Jul 2021 |
| MMOBILion Systems | Series C | $60M | Jul 2021 |
| Pulmocide | Series C | $92M | May 2021 |
| OOxbotica | Series B | $13.8M | Apr 2021 |
 Uniformity Labs | Series B | $38.4M | Feb 2021 |
| OOxbotica | Series B | $47M | Jan 2021 |
Page 1 of 3
Top Co-Investors
Hostplus9 shared
Pfizer Ventures9 shared
M Ventures8 shared
SV Health Investors7 shared
Octopus Ventures6 shared
Parkwalk Advisors6 shared
Sofinnova Partners6 shared
Oxford Science Enterprises5 shared
BGF5 shared
Andera Partners5 shared
RA Capital Management5 shared
British Patient Capital4 shared
Robert Bosch Venture Capital4 shared
British Business Bank4 shared
Arix Bioscience4 shared
Schroders Capital4 shared
Omega Funds4 shared
Avidity Partners4 shared
The Invus Group, LLC4 shared
Oxford University4 shared
Last updated: 7 October 2026